Research Studies

Inclusion Criteria: 1) Male/Female age > 18 2) Biopsy proven Fibrillary GN within 3 years of study randomization

Inclusion Criteria: 1. Stable Maximum RAAS inhibition X 4 weeks prior to randomization Note: Maximum RAAS inhibition will be left to the discretion of the site PI 2. eGFR > 25 mls/min calculate by the CKD-EPI formula 3. UP/Cr ratio > 2000 mg/gm 4. Blood pressure targeted to < 140/90 at the time of randomization Exclusion Criteria; 1. Patients with MGUS and history of myeloma WILL NOT be eligible 2. Patients with active viral production of either hepatitis B or C as evidence by historical PCR test positive for active viral shedding 3. HIV seropositivity 4. Renal biopsy data with > 50% Interstitial Fibrosis 5. Patient with active or a known history lymphoma 6. Patients with insulin Dependent diabetes mellitus will be excluded Note: patients with Type II diabetes mellitus that are well controlled WITHOUT the need for insulin WILL be eligible for the study. 7. Patients with Type II non-insulin dependent diabetes WILL be eligible provided the renal biopsy does not show nodular Kimmelstiel Wilson lesions. 8. Patients receiving steroids, MMF, cyclophosphamide, Azathioprine or other immunosuppressive agent with 4 weeks of study randomization Note: Washout of these medications will be allowed at the screening visit 9. Patients having received Rituximab or B cell modifying biologic therapy within 6 months of randomization